BCL2 and acute promyelocytic leukemia: The patient had a good tolerance to VEN, and the complete hematologic response indicated the significant efficacy of VEN in this case, suggesting that Bcl-2 inhibitors may become an effective salvage therapy for relapsed/refractory APL patients.